News Conference News ACC 2024 BE ACTIVE: Gaming for Points and Money Can Boost Step Counts L.A. McKeown April 11, 2024
News Conference News ACC 2021 Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF Yael L. Maxwell May 16, 2021
News Conference News ACC 2020 Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT Todd Neale April 02, 2020
News Conference News ACC 2019 REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events Yael L. Maxwell March 22, 2019
News Conference News ACC 2019 Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom Michael O'Riordan March 20, 2019
News Conference News ACC 2018 High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab Michael O'Riordan March 20, 2018
News Conference News ACC 2018 Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis Michael O'Riordan March 14, 2018
News Conference News ACC 2018 ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit Michael O'Riordan March 10, 2018
News Conference News ACC 2018 ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last Shelley Wood March 05, 2018
News Conference News ACC 2017 Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them Yael L. Maxwell March 23, 2017
News Conference News ACC 2017 SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab Yael L. Maxwell March 17, 2017
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017